In response to potential tariffs announced by President Trump, Eli Lilly and Company has recently announced plans to boost its U.S. manufacturing capacity. This move is seen as a proactive step to mitigate tariff risks and strengthen domestic production, which could benefit American workers and contribute to local economic resilience.

Eli Lilly’s PAC, Lilly PAC, contributed over $180,000 to both Republican and Democrat candidates in House and Senate races. Additionally, CEO David Ricks made a maximum individual contribution to a Republican Congressman, signaling a level of executive political engagement that raises concerns about corporate influence in democratic processes.

Shareholders, led by groups like SEIU and Change Finance, have proposed measures to compel Eli Lilly to disclose detailed information on its direct and indirect lobbying expenditures. The proposals argue that the company's current disclosures are insufficient, risking reputational harm and aligning with opaque political spending practices that can underpin authoritarian influence. Despite the company's claims of having substantially implemented these measures, the SEC's disagreement highlights concerns over transparency in its political engagements.